PRELI domain-containing 1 pseudogene 6 (PRELID1P6)

PRELI domain-containing 1 pseudogene 6 (PRELID1P6) is a long noncoding RNA pseudogene closely related to the PRELID1 gene. Although classified as a pseudogene, PRELID1P6 is upregulated in glioma and correlates with poor patient survival. Functional studies demonstrate that PRELID1P6 promotes glioma cell proliferation and inhibits apoptosis by stabilizing the protein hnRNPH1, leading to increased TRF2 expression, altered splicing, and activation of the oncogenic Akt/mTOR signaling pathway. Knockdown of PRELID1P6 blocks cell cycle progression and enhances apoptosis in glioma cells. Its role appears to be regulatory, functioning at the RNA level by interacting with RNA-binding proteins (notably hnRNPH1) and potentially competing with microRNAs (such as miR-1825)[1]. PRELID1P6 is not a receptor, enzyme, or druggable target in the classic sense, but it may serve as a novel prognostic biomarker and a candidate for research in the context of glioma biology and therapeutic resistance[1].

Other names

PRELID1P6PRELI domain containing 1 pseudogene 6

Drugs: Inhibition of the Akt/mTOR signaling pathway (MK2206). Endogenous: Stabilization of hnRNPH1, activation of Akt/mTOR pathway, promotion of alternative splicing, and suppression of apoptosis.